Functional Diagnostics

Healgen Scientific LLC is a global in-vitro diagnostics (IVD) developer and manufacturer established in 2007 in Houston, Texas. The company specializes in rapid point-of-care (POC) diagnostic testing technologies across multiple therapeutic areas: infectious diseases (COVID-19, influenza, Strep A), toxicology (drug screening, fentanyl/xylazine residue detection), fertility and women's health, oncology, cardiovascular, and metabolic disorders. Healgen's product portfolio includes rapid test cassettes, cups, and oral fluid devices—many FDA 510(k) cleared and CLIA-waived. Notable products include the Accurate® Multi-Drug Urine Drug Screen Cup (18-in-1 detection), Rapid Check® COVID-19/Flu A&B Antigen Test (available for both professional and OTC use), Fentanyl Rapid Tests, Strep A tests, and recently FDA De Novo-cleared Accurate® Oral Fluid Device. The company markets solutions to healthcare providers, workplace testing programs, public health organizations, and consumers. Healgen maintains global service centers and business partnerships across multiple countries and regions. Manufacturing and quality systems support FDA and international regulatory compliance.

HEINE OPTOTECHNIK is a German manufacturer of diagnostic and examination instruments serving medical professionals across multiple specialties. The company specializes in precision optical and illumination systems for direct and indirect visualization. Core product lines include dermatoscopes (DELTA series with UV and digital documentation capabilities), otoscopes and ophthalmoscopes (BETA, mini 3000, K180 LED series), laryngoscopes with reusable and disposable blades and video laryngoscope systems (visionPRO), slit lamps for ophthalmic examination (HSL 150), binocular indirect ophthalmoscopes (OMEGA and SIGMA series), and surgical loupes with integrated headlights (ML4, MicroLight2, LoupeLight2). The product portfolio also includes diagnostic sets combining multiple instruments, examination lights, stethoscopes, and sphygmomanometers for general medicine and ENT. HEINE offers extensive accessories including power sources (rechargeable and battery handles, charging stations), replacement bulbs (LED HQ modules and xenon-halogen), reusable and disposable specula/tips, protective cases, and batteries in multiple voltage configurations (2.5V to 6V Li-ion and NiMH). The company serves general medicine, ENT, ophthalmology, laryngology, dermatology, anesthesiology, and veterinary medicine. Products feature LED and fiber-optic illumination technology with focus on durability, ergonomics, and clinical reliability.

Mindera Health develops precision medicine diagnostics for dermatological conditions, specifically psoriasis. The company's flagship product, Mind.Px™, is a non-invasive diagnostic patch that captures thousands of RNA transcripts from a penny-sized skin sample in approximately five minutes. The device employs Dermal Intelligence™ technology to enable scalable collection and analysis of individualized genetic information, providing actionable, data-driven treatment guidance for patients, providers, and payers. Mind.Px is designed to support biologic therapy selection for psoriasis patients, reducing trial-and-error treatment approaches. The company markets directly to healthcare providers and patients, offering physician resources, online test ordering, and patient education materials. Mindera Health has received regulatory approval from the New York State Department of Health as of April 2026, enabling national availability across all 50 states. The platform combines genomic RNA analysis with clinical dermatology to support precision treatment decisions. Target users include dermatologists, rheumatologists, and other providers managing psoriasis patients seeking to optimize biologic therapy outcomes.

Echolight S.p.A. is an Italian medical device manufacturer specializing in bone density assessment and osteoporosis diagnosis. The company originated as a spin-off from Italy's Consiglio Nazionale delle Ricerche (CNR) and markets the EchoS system—a non-ionizing radiation bone densitometer that uses proprietary Radiofrequency Echographic Multi Spectrometry (R.E.M.S.) technology. The EchoS device performs ultrasound-based scanning of the lumbar spine and proximal femur to evaluate bone mineral density (BMD), T-score, Z-score, and bone microarchitecture quality without exposing patients to ionizing radiation. Scan time is rapid: 80 seconds for spine assessment, 40 seconds for femur. The system produces immediate medical reports with fracture risk indices and body composition data. Key clinical advantages over dual-energy X-ray absorptiometry (DXA) and quantitative ultrasound (QUS) include radiation-free operation, portability, lack of need for certified operators or shielded rooms, and applicability to pediatric, pregnant, diabetic, oncology, and secondary osteoporosis patients. EchoS is available in both stationary and portable configurations. The company holds FDA clearance, CE marking, ISO 13485:2016 quality management certification, ISO 9001:2015 compliance, and multiple international regulatory approvals. Echolight's R.E.M.S. technology is recognized in Italian Ministry of Health clinical guidelines (ISS guidelines on fragility fracture diagnosis and risk stratification). The company engages in ongoing clinical validation at major international osteoporosis centers and participates in scientific symposia including WCO-IOF-ESCEO conferences.

MEDTOX Diagnostics, Inc. is a point-of-care diagnostic company specializing in rapid immunoassay-based drug screening devices. The company manufactures rapid test cassettes, screening cups, and automated readers for substance abuse testing across clinical, workplace, criminal justice, and hospital settings. Primary product lines include MEDTOX PROFILE® cassettes and MEDTOX EZ-SCREEN® cups for screening up to 11 drugs of abuse with results in minutes, and the MEDTOX Scan® automated reader system for high-throughput, convenient screening. The company also offers a fentanyl test device recently cleared by FDA. MEDTOX serves hospitals, workplace wellness programs, clinical trial sponsors, and criminal justice agencies. As of 2026, the company is transitioning its trade name to Labcorp Point of Care under parent company Labcorp ownership. Products are designed for rapid point-of-care screening and typically achieve results within minutes of sample collection. The company provides training and customer support resources for clinical and administrative users.

Darmiyan, Inc. is a neuroscience-driven AI and medical imaging software company developing diagnostic tools for early detection and monitoring of neurodegenerative diseases, specifically Alzheimer's disease and dementia. The company's core technology leverages over four decades of pioneering brain research combined with advanced machine learning and medical image processing to analyze cellular-level changes in brain MRI scans. BrainSee, Darmiyan's flagship FDA De Novo-approved software, utilizes proprietary algorithms to quantify microscopic tissue architecture changes (voxel-level analysis) within standard clinical-grade MRI scans, enabling non-invasive early disease detection and patient-specific monitoring of therapeutic responses. The company targets three primary markets: early Alzheimer's detection in at-risk populations, objective measurement of patient response to interventions, and biomarker development for pharmaceutical drug development programs. Darmiyan's technology is designed around four core pillars: high diagnostic accuracy, non-invasiveness, seamless integration with existing MRI infrastructure, and global accessibility. The platform operates without requiring specialized imaging hardware, positioning it for broad adoption across healthcare settings. FDA Breakthrough Designation was granted to BrainSee for its potential to improve treatment of Alzheimer's disease. Third-party clinical validation has been completed in the US and Canada by independent research investigators. The company serves healthcare providers, pharmaceutical development teams, academic medical centers, and clinical research organizations pursuing precision brain health screening and monitoring solutions.

BrainSpec, Inc develops a cloud-based software platform for Magnetic Resonance Spectroscopy (MRS) analysis. The platform provides non-invasive 'virtual biopsy' capability by measuring brain metabolite concentrations at precision levels 10,000 times lower than conventional MRI. BrainSpec Core™ combines a linear combinations model post-processing backend with a user-friendly web interface for clinicians and researchers. The platform supports cross-vendor MRI compatibility, enables precision metabolite measurement, and provides automated reporting with cloud-based processing to ensure access to cutting-edge analytical algorithms. Applications include assessment of brain tumors, Alzheimer's disease, Multiple Sclerosis, and other neurological conditions. The company has developed proprietary reference databases of normal and diseased brain chemistry to streamline MRS interpretation to clinical utility standards comparable to routine blood testing. The platform is currently in the pre-market stage with FDA clearance pending. The company is accepting a limited number of pilot research sites. Over 28,000 publications document clinical applications of MRS technology.

Medi/Nuclear Corporation is a manufacturer and distributor of specialized lung imaging systems for nuclear medicine. Since 1973, the company has focused exclusively on radioaerosol and xenon delivery systems for ventilation lung scans, serving nuclear technicians, radiologists, and physicians. Their proprietary systems employ advanced nebulizer technology producing fine and ultra-fine particles for superior alveolar deposition and image quality in both SPECT and planar imaging modalities. The company's product lines include the Aero/Vent and Insta/Vent radioaerosol delivery systems with unidirectional airflow design, HEPA filtration, and multiple delivery options (mouthpiece shields, face masks, ventilator-compatible kits). All systems emphasize safety with enhanced radioactive contamination and infection control features, supported by comprehensive training materials and appropriate use criteria documentation.

Phase Scientific International Limited develops proprietary diagnostic technology and rapid testing solutions for early disease detection, with focus on cancer and infectious diseases. The company's core innovation is PHASIFY™, a molecular detection platform that enables faster, easier identification of target biomarkers compared to conventional diagnostics. PHASIFY™ powers three product and service lines: INDICAID® at-home rapid tests for point-of-care use; INDICAID lab™ at-home laboratory testing kits; and PHASE lab, a clinical laboratory service offering cancer and infectious disease testing. Recent product launches include FebriDx®, a respiratory pathogen test awarded FDA CLIA waiver (March 2026), and urine-based HPV screening for cervical cancer detection. The company markets solutions for cancer screening, cervical health monitoring, and respiratory/infectious disease diagnostics. Manufacturing and regulatory capabilities include FDA CLIA certification and active clinical research partnerships. The company has raised $34 million Series A funding and maintains operations in Asia and North America, positioning itself as an innovator in preventive diagnostics and non-invasive biomarker detection.

Acarix AS is a cardiac diagnostics company specializing in point-of-care acoustic-based diagnostic solutions for early coronary artery disease (CAD) assessment. The company's flagship product, CADScor® System, uses highly sensitive acoustic technology and advanced computational processing to analyze coronary blood flow and calculate patient-specific CAD risk scores. The system provides non-invasive, radiation-free risk stratification for patients presenting with chest pain or shortness of breath, with demonstrated negative predictive value of at least 96%. CADScor® System has been deployed in over 60,000 patient assessments since 2017 and is supported by 15+ years of research and development covered by 45 patents. The technology has received FDA De Novo clearance as a diagnostic aid for symptomatic patients with suspected CAD and is CE-marked in accordance with EU MDR 2017/745. Clinical evidence from multiple published studies involving over 6,000 patients demonstrates the system's diagnostic performance and utility compared to standard stress testing. The platform enables immediate risk stratification at point of care, potentially reducing unnecessary advanced diagnostic procedures in up to 40% of patients. Acarix targets healthcare professionals and facilities seeking accessible, cost-effective cardiac risk assessment tools that can be deployed regardless of geographical location or socioeconomic constraints.

Furuno Electric Co., Ltd. is a diversified manufacturer of marine navigation, positioning, and medical equipment. Primary business focuses on marine electronics for recreational boats, merchant marine, fishing vessels, and workboats, including fish finders, sonar systems, multi-beam sonars, marine radar, GPS/GNSS chart plotters, autopilots, and integrated navigation displays. The company also manufactures GPS/GNSS receiver chips and modules for positioning and timing applications, including 5G network infrastructure. In the medical segment, Furuno produces clinical chemistry analyzers and ultrasound bone densitometers for diagnostic and monitoring applications. The company provides navigational equipment training and coastal monitoring systems. Furuno operates with advanced capabilities in GNSS timing technology, autonomous navigation solutions, cyber security, and remote monitoring platforms. The organization serves global maritime markets and has expanded into industrial positioning and healthcare diagnostics. Products meet international maritime standards and regulatory requirements for marine equipment.

Instanosis Inc. develops high-sensitivity diagnostic technology for rapid drug detection in clinical, harm reduction, forensic, and law enforcement applications. The company manufactures FDA-cleared, CLIA-waived dipstick and test strip products for detecting fentanyl, xylazine, and nitazene in human urine and other biological samples. Products are reported to be 25 times more sensitive than competitor alternatives and have been validated in clinical settings with over 1,000 urine samples. Instanosis supplies hospital-grade drug detection systems for healthcare facilities, rapid response kits for outreach and shelters, field testing solutions for forensic teams, and distributes through GPOs and medical distributors. The company is NIH-funded and manufactures all products in the United States. Their diagnostic portfolio includes lateral flow assays and monoclonal antibody reagents (anti-fentanyl Clone H16) for ELISA and immunoassay development. The company targets clinical trial support, disease diagnosis and monitoring, overdose response, and harm reduction programs.

Perry Dynamics is a rehabilitation and sports medicine equipment manufacturer specializing in balance assessment and training systems. The company's flagship product, the PROPRIO® Reactive Balance System, is a patented technology platform designed to assess, measure, and train neurologic, orthopedic, and vestibular disorders affecting dynamic balance, posture, strength, and mobility. The system serves a diverse clinical population ranging from geriatric patients at fall risk to elite athletes, military personnel, and individuals recovering from neurological conditions such as stroke and Parkinson's disease. The PROPRIO® system is recognized in clinical education, having been featured in Umphred's Neurological Rehabilitation 6th edition, and is used across multiple healthcare and training environments. Perry Dynamics offers flexible acquisition options including equipment rental programs. The company utilizes state-of-the-art patented technology incorporating vestibular and somatosensory assessment principles based on peer-reviewed neuroscience research. Products are suitable for rehabilitation clinics, sports medicine facilities, military medical centers, and educational institutions.

Logos Systems International manufactures digital camera-based quality assurance phantoms for proton therapy and X-ray beam systems used in radiation oncology. The company specializes in 3D and 2D beam phantoms that perform end-to-end measurements with superior precision and speed, replacing traditional film-based measurement approaches. Product lines include the XRV-3000 Eagle and XRV-4000 Hawk beam profiler phantoms with modular accessories such as the LCW-300 stepped wedge and Proton Beam Range Verification modules for imaging Bragg peaks in proton and heavy ion beams. The company also provides BeamWorks client-server software for data analysis and quality assurance workflows. Applications encompass linac and proton beam QA, FLASH radiotherapy, proton arc therapy, and isocenter analysis (Starshot methodology). Target customers include radiation oncology departments, treatment centers, and medical physics programs requiring regulatory compliance and precision dosimetry verification. Products support real-time 3D beam vector and profile capture across 360-degree rotations and integrate high-energy radiation detection with precision two-dimensional metrology for comprehensive beam characterization.

Unite Medical is a veteran-owned B2B wholesale medical supplies distributor serving healthcare professionals and providers nationwide. The company specializes in FDA-registered and ISO 13485-certified medical devices and consumables, offering member-only wholesale pricing with same-day shipping capabilities. Primary product lines include COVID, flu, and diagnostic test kits; N95 respirators and medical masks; and orthopedic bracing solutions. All products meet regulatory standards and are sourced from ISO 13485-certified manufacturers. Beyond distribution, Unite Medical provides consulting services for product commercialization, including CMS/PDAC credential acquisition and private-label manufacturing support to help healthcare companies bring products to market. The company emphasizes fast order processing, secure checkout, and expert guidance for healthcare procurement professionals.

Mauna Kea Technologies is a global medical device company specializing in Confocal Laser Endomicroscopy (CLE) and in vivo cellular imaging. The flagship Cellvizio® platform delivers real-time histological visualization during endoscopy procedures across gastroenterology, pulmonology, urology, and neurosurgery, enabling physicians to accelerate diagnosis, inform treatment decisions, and guide surgical interventions with cellular-level precision. FDA-cleared and CE-marked, Cellvizio has been used in over 100,000 patient procedures worldwide. The company partners with industry leaders including Johnson & Johnson and Telix Pharmaceuticals to expand therapeutic applications in precision medicine, cancer detection, and early intervention across multiple clinical specialties.

Advanced Tactile Imaging, Inc. develops pioneering biomechanical mapping and digital twin technologies for women's pelvic healthcare. The company designs and manufactures novel diagnostic devices that quantify tactile properties of vaginal and pelvic floor tissues to support clinical evaluation and diagnosis of pelvic floor dysfunction, cervical conditions, and preterm birth risk. Primary product portfolio includes the Vaginal Tactile Ultrasound Imager (TIUSv), which combines tactile imaging with ultrasound fusion for functional assessment; the Vaginal Tactile Imager (VTI), a standalone tactile diagnostic device; and the Cervix Monitor (CM) for cervical assessment. The technology platform employs tactile ultrasound imaging methodology to provide objective, quantifiable biomechanical integrity scoring of pelvic floor tissues. The company has published peer-reviewed research in journals including Military Medicine, Open Journal of Obstetrics and Gynecology, Journal of Pelviperineology, and SCIRP, demonstrating clinical applications in spontaneous preterm birth prediction and comparative analysis across military and civilian populations. In 2025, Advanced Tactile Imaging received a USA patent for its method of characterization of the female pelvic floor with biomechanical integrity scoring. The company exhibits at major international medical trade shows, including MEDICA (Dusseldorf, 2025), indicating active market engagement. Clinical evidence and patent portfolio support regulatory development pathway for diagnostic medical devices in obstetrics and gynecology.

MedImage, Inc. is a specialized medical software company providing dedicated reading and visualization software for nuclear medicine, molecular imaging, and PET/CT imaging. With over 25 years of operational history, MedImage develops MedView (formerly DELTAmanager), a fully 64-bit cross-platform application available for Windows and macOS. The software is designed for PACS-integrated review of nuclear medicine, PET, PET-CT, SPECT, SPECT-CT, and MR/PET imaging modalities. MedView is positioned as a flexible, lightweight alternative to standard PACS workstations, emphasizing ease of configuration and rapid serial image review for multidisciplinary clinical meetings and presentations. The company integrates with value-added partners including INVIA Medical Imaging Solutions and Syntermed for quantitative cardiac and brain imaging analysis. Target users include nuclear medicine physicians, radiologists, and imaging centers seeking specialized molecular imaging review capabilities. The software supports clinical workflows in both institutional and multi-provider settings.

Integrity Medical Products is a B2B supplier of medical equipment accessories, replacements, and consumables for healthcare facilities. The company specializes in patient monitoring cables and sensors (SpO2, ECG, invasive/non-invasive blood pressure) compatible with major monitor brands, available at 30–60% savings versus OEM pricing, with one-year warranties. Product portfolio includes monitor mounting arms and cable management systems (five-year warranty), nurse call accessories with pillow speakers (two-year warranty), medical carts and stands for monitors, ventilators, and suction pumps, and hospital furniture including overbed tables, bedside cabinets, fetal monitoring carts, bassinets, stools, and chairs with antimicrobial construction. Integrity also supplies suction and oxygen therapy products (analog and digital suction regulators, portable suction pumps, flowmeters, gas regulators, cylinder carts, high-pressure hoses) and offers patent-pending Integrated Flowmeter technology. Additional product lines include diagnostic systems (ophthalmoscopes/otoscopes with Welch Allyn compatibility), endoscopy/OR monitors and video accessories (wireless transmitters, fiber optic light cords, custom screen protectors), operating room table and stretcher pads (gel, foam, and self-adjusting air options for pressure ulcer prevention), and bed and stretcher accessories with custom fabrication available. The company targets hospitals, surgical centers, and critical care facilities, emphasizing affordability, compatibility with existing infrastructure, and practical solutions to institutional procurement challenges.

Radiation Products Design, Inc. (RPD) is a specialized manufacturer and supplier of radiation therapy, diagnostic imaging, and nuclear medicine accessories and equipment. Based in Albertville, Minnesota, RPD serves medical physics, radiation oncology, and nuclear medicine departments across the United States. The company's product portfolio spans multiple therapeutic and diagnostic domains: radiation therapy positioning and immobilization systems (thermoplastic masks, vacuum cushions, head supports, breast positioning devices); brachytherapy applicators and accessories for both low-dose rate (LDR) and high-dose rate (HDR) gynecological applications; dosimetry and quality assurance equipment including build-up caps for ion chambers (Farmer, Exradin, PTW, Scanditronix/Wellhofer models), MOSFET and diode systems, electrometers, and radiation area monitors; CT simulator and imaging accessories such as CT chambers, phantoms, marking systems, and alignment lasers; shielding products including lead blocks, eye shields, tungsten shields, and mobile radiation barriers; calibration phantoms and water phantom systems; PET/nuclear medicine workstations, storage containers, and shipping systems; and sterilization/disinfection equipment and trays. RPD manufactures custom block room products (alloy dispensers, styrofoam blocks, cooling plates), bolus materials (Aquaplast, SuperFlab, moldable options), and precision beam modification tools. The company also supplies marking and positioning consumables, measuring instruments, lead-lined containers, and quality control devices (ISIS QA phantoms, beam analyzers). Products are compatible with major linear accelerator and imaging equipment manufacturers including Varian, Siemens, and Elekta. The company maintains a comprehensive PDF catalog and offers custom manufacturing for specialized applications. RPD serves hospital radiation oncology departments, medical physics groups, nuclear medicine facilities, and diagnostic imaging centers, providing both stock products and made-to-order solutions for radiation protection, dose verification, and treatment planning.

Sun Nuclear Corporation is a global leader in radiation oncology quality assurance (QA) solutions, serving over 6,000 healthcare facilities in more than 130 countries. Founded in 1984 and headquartered in Melbourne, Florida, the company specializes in comprehensive QA platforms for radiation therapy and diagnostic imaging, with solutions deployed in over 90% of U.S. cancer treatment centers and 60% of global facilities. Sun Nuclear provides advanced dosimetry verification, machine QA, patient-specific plan verification, and AI-powered treatment planning tools. The portfolio includes proprietary detector technologies, phantom systems, and integrated software solutions designed to enhance patient safety and streamline clinical workflows. In 2021, Sun Nuclear was acquired by Mirion Technologies, strengthening its position in radiation safety innovation. The company offers extensive clinical support, training, and service backed by over 300 years of combined team expertise and 34 patents in radiation oncology and diagnostic imaging QA.

BioCheck, Inc. is a leader in value-based diagnostics and data monetization, offering high-quality in vitro diagnostic immunoassay devices. The company manufactures and distributes a comprehensive range of diagnostic products including instruments, antibodies, and ELISA kits designed for clinical and research applications. Following the August 2021 acquisition of DRG International, BioCheck operates a global network with subsidiaries and offices across the USA, Germany, Russia, Poland, and Czech Republic, providing distribution capacity to customers in over 110 countries. The DRG:HYBRiD-XL® is a fully automated analyzer for immunoassays and clinical chemistry. Product lines span diagnostic ELISAs, chemiluminescent assays, and specialized antibodies for applications including diabetes diagnosis, endocrinology, prenatal/neonatal supervision, and thyroid function testing. BioCheck emphasizes value-based diagnostics—delivering cost-effective, evidence-based diagnostic testing to improve patient outcomes and reduce unnecessary testing—alongside healthcare data monetization and shared savings models. The company aligns with well-established diagnostic principles, focusing on accessible, reliable tools for hospitals, clinics, research laboratories, and resource-limited settings.

Medical Monofilament manufactures sensory testing monofilaments for diabetic foot ulceration and amputation prevention since 1999. The company holds FDA 510(k) clearance and operates as the only automated manufacturer of precision monofilaments in the U.S., utilizing a proprietary automated manufacturing process that ensures consistent quality and calibration. All products and components are manufactured domestically. Medical Monofilament is women-owned and operated, serving healthcare providers and diabetic care programs with affordable, high-quality diagnostic tools for neuropathy assessment and patient education in diabetes management.

Intramedical Imaging LLC manufactures and markets molecular imaging instruments for intraoperative cancer detection. The company has specialized in gamma probe technology since 1998, developing radioguided surgery solutions for sentinel lymph node mapping, radioactive seed localization, radioguided parathyroidectomy, and tumor localization. Their flagship product, the Node Seeker 2000 Gamma Probe, features the highest published sensitivity and resolution in the market—reportedly twice that of competing devices like the Neoprobe. The system includes a user-friendly touchscreen tablet control unit with real-time count display and battery monitoring. All probes are certified for Hydrogen Peroxide (H2O2) sterilization by Sterrad and Sterris, meeting OR infection control requirements. The Node Seeker system is designed for breast cancer, melanoma, and parathyroid surgery applications. The company serves surgical oncologists and OR staff in hospital and surgical center environments. Products are intraoperative molecular imaging devices for use during cancer surgery and endocrine procedures.

SamanTree Medical SA is a Swiss medtech company specializing in intraoperative digital pathology solutions. The Histolog® Scanner is a real-time tissue imaging system based on massively parallel confocal microscopy technology, enabling surgeons to visualize fresh tissue microstructures without specimen damage. The system provides rapid specimen preparation (15 seconds) and scanning (~1 minute per surface) with 2 µm per-pixel resolution, delivering high-resolution imaging of tissue surfaces for tumor margin assessment during cancer surgery. The scanner maintains specimen integrity while providing microstructural information to support surgical decision-making across breast, prostate, lung, and brain cancer procedures. Complementary consumables include the patented Histolog Dip (fluorescent stain) and single-use Histolog Dish. Digital collaboration tools enable remote physician consultation and annotation. FDA-cleared and CE-marked globally.

UltraSPECT USA, LLC is a specialized provider of image reconstruction software and algorithms for nuclear medicine gamma cameras. The company develops proprietary Wide-Beam Reconstruction (WBR™) technology that enhances imaging performance in cardiac and oncology applications. Their flagship products—Xpress.Cardiac™, Xpress3.Cardiac™, and Xpress/Xact.Bone™—enable clinicians to acquire diagnostic-quality SPECT images with significantly reduced radiopharmaceutical doses, shortened acquisition times, or both simultaneously. Applications include rest/stress cardiac studies, gated cardiac imaging, prone positioning, attenuation correction, and bone imaging protocols. UltraSPECT's solutions improve patient safety and comfort while maintaining or enhancing diagnostic image quality across nuclear medicine practices.

Johnson MedTech LLC is a medical device subsystem design and manufacturing company specializing in innovative, high-quality component solutions for critical care, surgical, diagnostic, and medication delivery applications. The company manufactures advanced medical device subsystems including critical care testing sensor strips for point-of-care diagnostics, surgical instrument embedded systems (hernia tackers), precision patch pumps for insulin and hormone delivery, solenoid valve manifolds for sequential compression devices (DVT prophylaxis), peristaltic blood pumps for accurate flow control, and autoinjectors for safe medication delivery with needle management. Johnson MedTech also produces disposable single-patient-use EKG patches. The company serves OEM medical device manufacturers requiring miniaturized, efficient hardware and software designs with regulatory compliance. Manufacturing capabilities include embedded systems engineering, precise dosing mechanisms, and medical-grade component integration. Products target critical care monitoring, surgical applications, infusion and delivery systems, and point-of-care diagnostics. The company demonstrates commitment to quality and innovation with documented product launches in hormone delivery, disposable diagnostics, and advanced pump technologies.

Manheim Medical Supply is a privately owned and operated medical supply distribution company serving skilled nursing facilities, assisted living facilities, and hospices throughout Central Pennsylvania. The company provides comprehensive supplies and services including wound care, diagnostics equipment, incontinence products, linen, nursing supplies, ostomy supplies, rehabilitation equipment, nutritional products, and pharmacy items. Manheim Medical Supply's experienced team offers personalized product selection assistance and consultative services to help healthcare facilities navigate industry changes. The company has built a reputation for integrity, quality products, and long-term customer partnerships.

Spectrum Dynamics Medical is a specialized medical device manufacturer focused on personalized molecular imaging and nuclear medicine applications. The company develops high-definition, solid-state nuclear imaging technology using proprietary 360° CZT (Cadmium Zinc Telluride) detector technology. Their portfolio includes the D-SPECT Series, an advanced digital SPECT imaging system designed for cardiology applications featuring rapid myocardial perfusion imaging (scan times as fast as 2 minutes), dynamic imaging for flow reserve calculation, and emission-based attenuation correction; and the VERITON-CT Series, the first ring-shaped SPECT/CT hybrid system enabling comprehensive total-body 3D imaging with an 80 cm bore size for expanded procedural capabilities. CZT solid-state detectors provide superior sensitivity and energy resolution compared to traditional NaI detectors, eliminating the need for photomultiplier tubes and enabling higher count rates. Spectrum Dynamics serves hospitals, cardiology clinics, diagnostic imaging departments, and nuclear medicine centers globally, with R&D facilities in Haifa, Israel and regional offices across North America, Europe, and Asia-Pacific.

DoseOptics manufactures BeamSite, an FDA-cleared Cherenkov imaging system that captures real-time video visualization of radiation therapy dose delivery to patients during treatment. BeamSite is the first clinical system to provide direct visual verification of radiotherapy beam placement and dose delivery by imaging Cherenkov light emissions. The company offers two product lines: BeamSite for clinical use in radiation oncology departments, and BeamSite Research for laboratory and research applications. By enabling clinicians to visually verify radiation therapy in real time, BeamSite supports treatment quality assurance, reduces delivery errors, and enhances patient safety. Clinical evidence demonstrates that visualization can identify suboptimal treatments that would otherwise go undetected. DoseOptics also partners with Vision RT to offer DoseRT, a Cherenkov imaging system integrated with Surface-Guided Radiation Therapy (SGRT) technology. The company serves radiation oncologists, medical physicists, radiation therapists, hospital administrators, and research institutions.

Watmind USA is a healthcare biotechnology company specializing in rapid diagnostic testing devices for COVID-19 and influenza detection. The company's flagship product, SpeedySwab™ Rapid COVID-19 + Flu A&B Antigen Self-Test, is an FDA Emergency Use Authorized (EUA) point-of-care test designed for both at-home self-testing and professional healthcare settings. The test uses lateral flow assay (LFA) technology to detect SARS-CoV-2 variants, sub-variants, and influenza A and B viruses from anterior nasal swabs in approximately 15 minutes. Available in single-test, two-test, and four-test configurations, SpeedySwab™ is authorized for self-collected nasal swabs in individuals aged 14 and older, and adult-collected swabs for children aged 2 and older. The product has a 21-month shelf life and is distributed through major retailers and online channels. Watmind USA emphasizes accessibility, accuracy, and convenience in its product design and positioning. The company operates through exclusive distribution partnerships; Biolabs International LLC serves as the exclusive distributor based in San Diego, California. Watmind USA holds FDA EUA authorizations for both point-of-care (PoC) and over-the-counter (OTC) versions of SpeedySwab™, supporting widespread availability in pharmacies, grocery stores, and healthcare provider offices. The company serves families, travelers, healthcare systems, and public health agencies focused on rapid respiratory virus screening and outbreak detection.

Endure Industries is a medical device manufacturing and distribution company based in Homer, New York, specializing in single-use surgical items with a primary focus on anesthesia delivery systems and airway management devices. The company serves hospitals, surgery centers, EMS providers, nursing homes, and the U.S. Department of Defense. Their product portfolio encompasses anesthesia breathing circuits, endotracheal tubes, oxygen delivery devices (including Venturi masks and BVM resuscitators), ETCO2 cannulas, cautery blades, wound care supplies, medical tapes, gauze, syringes, needles, and medical gloves. Endure is FDA-compliant and women-owned, emphasizing transparent procurement practices with competitive pricing. The company operates 24/7 customer support and offers free shipping on orders over $75.

Aptitude Medical Systems is a deep-tech healthcare company specializing in advanced molecular diagnostic testing platforms that deliver lab-quality results without requiring specialized laboratory infrastructure. Founded in 2011 and based in Goleta, California, the company's flagship Metrix platform enables rapid, accurate infectious disease diagnostics in multiple settings including urgent care centers, physician offices, hospitals, pharmacies, and homes. The FDA-authorized Metrix COVID-19 test provides rapid detection of COVID-19 and flu viruses using saliva or swab samples. The company is expanding its molecular testing portfolio to cover respiratory health, sexual health, and other infectious disease conditions. Aptitude's mission centers on democratizing diagnostics by making molecular-level testing accessible, affordable, and operationally simple for healthcare providers and patients globally, while addressing cost and usability challenges inherent in traditional laboratory-based diagnostics.

BioMedix (Collaborative Care Diagnostics, LLC) is a vascular diagnostics company founded in 2004 specializing in non-invasive physiologic assessment systems for identifying peripheral artery disease (PAD) and managing population health in value-based care settings. The company's primary product line includes PADnet, a flexible and customizable vascular assessment system designed for clinical settings to detect hidden peripheral vascular disease through non-invasive testing, and PADnet Xpress, a portable, rapid screening solution optimized for population health management. BioMedix Xchange is a population health management platform that aggregates test results and patient history for centralized analysis and specialist review. The company enables secure remote transmission of test data and patient information to specialists for interpretation, supporting distributed care models and reducing patient travel burden. PADnet systems are used by podiatrists, primary care physicians, vascular surgeons, cardiologists, and interventional specialists across physician practices, hospitals, and health systems. Products integrate with multi-specialty groups to streamline workflow and improve care coordination between primary physicians and specialists. The company emphasizes training and support for clinical staff to ensure proper testing protocols and diagnostic confidence. Applications include screening high-risk populations (diabetics, smokers, patients over 65), evaluation of intermittent claudication and limb pain, identification of candidates for revascularization procedures, and ongoing management of vascular disease in value-based payment models. The platform supports seamless sharing of diagnostic results across care networks and remote specialist interpretation via secure internet-based systems.

LumiQuick Diagnostics Inc. is a minority-owned, privately-held manufacturer of high-quality point-of-care testing and immunoassay kits for the global in vitro diagnostics market. Founded in 2006 and based in Santa Clara, California, the company develops rapid diagnostic tests in multiple formats including test cups, cards, dip tests, and multi-panels. Product lines span infectious disease detection (Dengue, Zika, Chikungunya, COVID-19), drugs of abuse screening, disease markers for cardiac and cancer indicators, fertility hormones, vitamin D assessment, oxidative stress measurement, veterinary diagnostics, food safety testing, and biological threat agent identification. LumiQuick's QuickProfile™ branded assays leverage immunochromatographic technology for qualitative and quantitative detection. The company also manufactures ELISA-based platforms and offers the FDA EUA-cleared Boson Rapid SARS-CoV-2 Antigen Home Test. Products are sold in bulk through local and international distributors, targeting clinical laboratories, point-of-care settings, and compliance screening applications.

Radiological Imaging Technology is an industry-leading manufacturer of quality assurance software solutions for medical physics and radiation therapy. With over 30 years of expertise, RIT provides comprehensive QA software for linear accelerators (TG-142), specialized routines for TomoTherapy (TG-148) and CyberKnife (TG-135) systems, and automated phantom analysis for diagnostic imaging. The RIT Family of Products delivers patient, machine, and imaging QA capabilities to help healthcare institutions meet regulatory and accreditation guidelines. The company serves medical physicists and imaging departments both domestically and internationally, offering workflow automation, remote QA capabilities, and compliance-focused tools engineered to ensure proper adherence to established therapeutic and diagnostic physics protocols.

Roche Diagnostics is a global leader in in vitro diagnostic (IVD) instruments, assays, and laboratory systems for clinical chemistry, molecular diagnostics, pathology, and specialty testing. The company manufactures high-volume automated analyzer platforms including the cobas® c 703 for clinical chemistry (2,000 tests/hour), cobas® 5800 system for consolidated automation and integration, and Digital LightCycler® System for digital PCR applications. Product offerings span core lab chemistry, hematology, immunochemistry, mass spectrometry solutions (including Ionify® steroid assays), tissue diagnostics with ready-to-use oncology assays, and blood-based biomarker testing (e.g., pTau181 for Alzheimer's-related amyloid pathology). The organization serves laboratory professionals, clinicians, researchers, and patients across multiple laboratory settings. Roche maintains FDA clearances and 510(k) approvals for its analytical systems and assays, with CLIA moderate-complexity categorization for specialized tests. The company provides comprehensive support including eLabDoc document library access (800,000+ documents), e-learning platforms, PACE/CEU accredited training, and clinical education resources. Manufacturing and regulatory operations are supported from US facilities including Indianapolis headquarters.

Bosch Healthcare Solutions GmbH is a subsidiary of Robert Bosch GmbH specializing in innovative diagnostic solutions and medical technology. Founded in 2015 and based in Waiblingen, Germany, the company develops point-of-care and laboratory diagnostic devices for healthcare professionals. The flagship Vivalytic platform is a versatile PCR-based molecular diagnostics system delivering results in approximately 39 minutes for multiple infectious disease tests, including COVID-19, bacterial meningitis, MRSA, sexually transmitted infections, and Candida auris. The Vivatmo product line offers non-invasive breath analysis technology for measuring FeNO (fractional exhaled nitric oxide) in asthma management, available as both clinical and home-monitoring devices. With approximately 150 employees and €121.5 million in annual revenue, Bosch Healthcare Solutions focuses on creating user-friendly diagnostic products for hospitals, clinical laboratories, physicians' offices, and nursing homes. The company emphasizes rapid turnaround times, accessibility, and integration with healthcare workflows through strategic partnerships and continuous product innovation.

Diag-Nose.io is a Melbourne-based biotechnology company specializing in precision diagnostics and therapies for chronic respiratory diseases including asthma, COPD, and chronic sinusitis. The company's flagship RhinoMAP platform combines nasal microsampling, proteomics, and AI-driven machine learning algorithms to decode airway biology and provide actionable clinical insights for ENT physicians. By analyzing patients' immune profiles and airway biology, Diag-Nose.io delivers personalized treatment recommendations that move beyond trial-and-error respiratory care. The ABEL Microsampler® device enables non-invasive nasal liquid biopsies for research and clinical diagnostics, with recent FDA and ARTG regulatory approvals. The platform targets treatment personalization and disease prevention through root-cause analysis, supporting precision medicine approaches for improved patient outcomes in respiratory disease management.

Q-linea AB is a Swedish infection diagnostics company founded in 2008, specializing in rapid antimicrobial susceptibility testing (AST) systems for sepsis and bloodstream infection management. The company's flagship product, ASTar, is a fully automated, CE-IVD marked system that delivers antibiotic susceptibility profiles directly from positive blood cultures in approximately six hours—significantly faster than traditional methods that require 48+ hours. ASTar operates with minimal hands-on time (less than two minutes) and provides accurate MIC (minimum inhibitory concentration) values through controlled inoculum protocols, integrating with electronic medical records for seamless laboratory workflows. Q-linea addresses a critical clinical need: sepsis affects approximately 50 million people globally each year with 11 million deaths, making rapid diagnosis and appropriate antibiotic selection essential for patient survival. The company holds CE-IVD approval in Europe and FDA 510(k) clearance in the US, and collaborates with partners like Thermo Fisher Scientific for product commercialization. Q-linea's mission focuses on improving sepsis treatment outcomes while reducing unnecessary antibiotic use and combating antimicrobial resistance.

Hermes Medical Solutions is a Sweden-based molecular imaging software company founded in 1976, pioneering innovations in nuclear medicine and molecular imaging. The company's flagship product, Hermia, is a comprehensive vendor-neutral software platform designed for nuclear medicine and molecular imaging departments. Hermia enables healthcare professionals to visualize, process, analyze, report, and archive imaging data from PET, SPECT, CT, and MRI modalities. The platform streamlines clinical workflows, provides advanced quantitative reconstruction tools (including SUV SPECT), and supports personalized dosimetry for theranostic applications. Hermia serves approximately 30,000 users across 70 countries and is used by university hospitals and healthcare providers globally. The software suite supports all clinical molecular imaging specialties and integrates seamlessly with existing hospital IT systems and DICOM-compliant equipment, regardless of manufacturer. Hermes has achieved regulatory clearances including FDA approval and CE marking, with recent ARTG listing in Australia.

MediBeacon Inc. is a medical technology company specializing in fluorescent tracer agents and transdermal detection technology for non-invasive physiological monitoring. The company's proprietary platform enables real-time measurement and monitoring of vital organ function through biocompatible fluorescent agents that are sensed through the skin via transdermal optical sensors. Primary clinical focus areas include nephrology (kidney function assessment via transdermal GFR measurement), gastroenterology (gut barrier permeability assessment), ophthalmology (fluorescent angiography for retinal vasculature visualization), and surgical applications (intraoperative visualization and identification of anatomical structures). MediBeacon's Transdermal GFR (TGFR) System received FDA PMA approval (P230019) and CE Mark for human clinical use. The company serves leading academic medical centers, research institutes, contract research organizations (CROs), and pharmaceutical companies globally for both preclinical research and clinical applications. MediBeacon maintains offices in St. Louis, Missouri (USA), Mannheim, Germany, and partnerships in Greater China through Huadong Medicine Co., Ltd.

Driving Force Company specializes in the VMA® (Vertebral Motion Analyzer), an FDA-cleared, patented spinal imaging system designed for personal injury clinics and regenerative medicine providers. The VMA® measures spinal motion quantitatively under weight-bearing, functional conditions—capturing vertebral rotation and translation with sub-millimeter accuracy that static imaging (MRI, X-ray) cannot detect. The system uses real-time motion tracking and patented automated diagnostic analysis to identify ligament instability, segmental dysfunction, and hidden instability in cervical and lumbar spine. Driving Force provides in-office implementation, clinical training, independent medical validation via board-certified radiologists, and business support to help clinics integrate motion-based imaging into workflows and build regional imaging ownership models. Primary markets include personal injury litigation support, workers' compensation diagnostics, and regenerative medicine treatment planning.

Ivy Biomedical Systems is the market leader in precision cardiac and respiratory gating monitors and modules for diagnostic imaging synchronization. The company manufactures specialized equipment used to synchronize radiographic image acquisition across all major imaging modalities, including nuclear medicine/molecular imaging (NM/MI), computed tomography (CT), magnetic resonance (MR), positron emission tomography (PET), and single photon emission computed tomography (SPECT). Their gating solutions enable clinicians to acquire high-quality synchronized images by triggering image capture at specific cardiac or respiratory phases, reducing motion artifacts and improving diagnostic accuracy. The company serves as an OEM partner to major imaging equipment manufacturers and provides comprehensive sales, service, and technical support globally.

Becton, Dickinson and Company (BD) is a global medical technology leader founded in 1897 with approximately $20.2 billion in FY2024 revenue. BD supplies a comprehensive portfolio spanning diagnostic and laboratory solutions, surgical products and instruments, medication management systems, and infection prevention technologies. The company pioneered disposable syringes (Plastipak™) and blood collection systems (BD Vacutainer®), and operates automated blood culture and diagnostic platforms. Through strategic acquisitions including CareFusion and C.R. Bard, BD expanded capabilities in medication management, surgical interventions, and hospital systems. Current offerings address ambulatory surgery centers, diagnostic accuracy and specimen collection workflows, patient safety and infection control, advanced clinical analytics through BD HealthSight Advisor, medication management optimization, and surgical efficiency. BD Incada™ Connected Care Platform represents the company's digital health integration strategy. With global operations across alternate sites, diagnostic labs, research areas, hospital units, pharmacy, and surgical suites, BD serves healthcare systems seeking integrated solutions to improve patient outcomes and operational efficiency.

Silver Lake Research Corporation develops, manufactures, and markets rapid point-of-care diagnostic test kits with proprietary EAP™-derived monoclonal antibodies. Founded in 1992, the company specializes in lateral flow immunoassays that deliver laboratory-grade accuracy and sensitivity in minutes at the point of care. The company operates an ISO 13485-compliant, FDA-registered US manufacturing facility—one of the largest independent automated production lines for lateral flow tests—enabling high-volume production of both proprietary products and contract-manufactured diagnostics. Key product lines include HemoTypeSC (hemoglobin phenotyping for sickle cell disease screening), WaterSafe (drinking water quality testing), and RapidBac (rapid urinary tract infection detection requiring no instrumentation). The company has marketed 150+ products and produced over 15 million test strips globally. Services include custom immunoassay development, bespoke assays for specific instruments, and private-label manufacturing. Silver Lake Research serves clinical laboratories, point-of-care testing environments, and contract manufacturing customers. The company emphasizes tangible innovation in antibody development and manufacturing partnerships, positioning itself as a turnkey solution provider for rapid diagnostic platforms.

EnteroTrack is a medical device company specializing in minimally invasive diagnostic equipment for eosinophilic esophagitis (EoE) management. The company manufactures and distributes the EnteroTracker®, a device used to perform the Esophageal String Test® (EST), a non-endoscopic, office-based procedure for collecting mucosal samples from the upper gastrointestinal tract. The EST enables clinicians to monitor esophageal inflammation in EoE patients, assess treatment response, evaluate food triggers, and reduce the need for repeated endoscopic procedures. The procedure involves a capsule attached to a string that patients swallow; the string remains in the upper GI tract for a physician-designated period and is then retrieved to collect fluid and mucus samples for analysis at reference laboratories. The test provides a liquid biopsy for disease-related biomarker analysis and eosinophil quantification, with published clinical data demonstrating 93.9% efficacy in distinguishing active EoE from treatment-associated remission. Medicare coverage for the EST became available, expanding patient access. EnteroTrack partners with academic medical centers including UC Denver Bioengineering, Children's Hospital Colorado, and University of Colorado Denver, and maintains relationships with advocacy organizations including APFED and CURED Foundation. The device is indicated for use in adult and pediatric patients. The company operates a growing network of test locations across the United States.

Pulmonx Corporation is a global medical technology company headquartered in Redwood City, California, with operations in Neuchâtel, Switzerland, founded in 1995. The company specializes in minimally invasive bronchoscopic interventions for severe emphysema and chronic obstructive pulmonary disease (COPD). Pulmonx pioneered bronchoscopic lung volume reduction (BLVR) technology and has established itself as a leader in interventional pulmonology solutions for patients unsuitable for or unresponsive to surgical intervention. The company's flagship product portfolio includes the Zephyr® Endobronchial Valve, a clinically validated device that reduces lung hyperinflation by occluding diseased airways, demonstrating significant improvements in lung function (FEV1), exercise capacity, and quality of life across multiple randomized controlled trials. The Chartis® Pulmonary Assessment System provides collateral ventilation assessment to optimize patient selection and treatment planning. The LungTraX Platform delivers cloud-based quantitative CT analysis for personalized treatment planning. Pulmonx's devices are FDA-approved and supported by extensive clinical evidence across four major randomized controlled trials, with over 100 published clinical summaries. The company maintains a global network of treating physicians and assessment centers, with rigorous credentialing criteria including specialized training, hands-on competency, and outcomes monitoring.

RTsafe is a medical technology company specializing in quality assurance solutions for radiation oncology and stereotactic radiosurgery. The company develops patient-specific anatomical phantoms using advanced 3D printing technology based on patient CT scans to enable precise dosimetry verification and pretreatment quality assurance. RTsafe's flagship product, the FDA-cleared PseudoPatient®, replicates individual patient anatomy for accurate dose measurement and treatment planning validation. The company also offers the Prime Phantom for linear accelerator quality assurance, the SBRT Phantom for abdominal stereotactic body radiotherapy planning, customized phantom services, and remote dosimetry audit services. RTsafe's solutions support radiation oncologists, medical physicists, and treatment centers globally in achieving minimum-achievable-risk radiotherapy through rigorous end-to-end treatment chain validation.

Medical Disposables Corp. is an FDA-registered supplier specializing in rapid diagnostic testing products and surgical instruments. The company offers comprehensive solutions across drug testing, infectious disease screening, and laparoscopic surgical devices. Primary product lines include: urine multi-panel drug tests (5, 10, 12, 13, 14-panel configurations), saliva drug tests, alcohol testing (EtG strips), infectious disease rapid assays (Strep A, COVID-19, Influenza A & B), fentanyl and emerging drug tests, fecal occult blood tests (FOBT), pregnancy and fertility tests, and temperature strips. Surgical inventory includes trocars (bladeless and bladed tip auto-locking models), clip appliers, forceps (Mixter and clinch variants), and monopolar electrodes for laparoscopic procedures. All products are sourced from manufacturers adhering to strict quality controls and regulatory standards. The company emphasizes CLIA waiver compliance, point-of-care testing capabilities, and supply chain reliability. Services include customized drug test cups and bulk purchasing support for clinical, workplace, institutional, and at-home applications. Medical Disposables Corp. operates same-day shipping (by 3 p.m. EST, Mon–Fri for US domestic customers) and free shipping over $75. The organization serves workplace screening programs, clinical monitoring, wellness assessments, rehabilitation facilities, and recovery programs across the United States and internationally.

ImpediMed is a medical technology company specializing in bioimpedance spectroscopy (BIS) devices for noninvasive clinical assessment and monitoring of fluid status and tissue composition. The company's flagship SOZO® Digital Health Platform is FDA-cleared and enables real-time measurement of body composition, fluid volumes, and tissue changes across multiple clinical applications. Primary use cases include early detection and monitoring of secondary lymphedema in cancer survivors, heart failure fluid management, medical weight management assessment, and wellness/longevity monitoring. The SOZO platform utilizes advanced BIS technology measuring 256 frequencies to separate intra- and extracellular fluid and deliver actionable insights at point of care. The company operates a cloud-connected SaaS model supporting personalized care monitoring across the patient treatment continuum, with global distribution in US, Europe, Australia, and other markets.

Vigilant Biosciences is a biotechnology company specializing in early oral cancer detection through innovative point-of-care diagnostic technologies. Founded in 2011 and based in Lakeway, Texas, the company develops the BeVigilant OraFusion System, a patented non-invasive saliva-based test that detects multiple biomarkers clinically associated with early-stage oral cancer. The system has received FDA Breakthrough Device Designation and IVDR approval for international expansion. With annual revenue of $22 million and approximately 16-22 employees, Vigilant Biosciences primarily serves dental practitioners and healthcare providers seeking to improve oral cancer detection rates and patient outcomes. The company addresses a critical clinical need, as oral cancer—the sixth most common human cancer globally—currently has 5-year survival rates below 50%, with over 70% of cases diagnosed at advanced stages. The BeVigilant OraFusion System enables chairside screening with high accuracy, transforming detection and improving survival outcomes through early intervention.

Vivid Vision Inc develops digital vision care solutions for diagnosis and therapeutic training of binocular vision disorders and visual field assessment. The company manufactures two core platforms: Vivid Vision (VV), an advanced vision training system for amblyopia, strabismus, and convergence insufficiency delivered via VR-based home training; and Vivid Vision Perimetry (VVP), a precision at-home microperimetry system for clinical visual field testing in retinal and glaucoma disorders. VVP is validated for use as a functional vision endpoint in clinical trials for geographic atrophy, age-related macular degeneration, and glaucoma therapeutics. The company also offers EYEBAB VT, a therapeutic exercise platform with dozens of vision activities for clinic-based intervention. With over 100,000 patients in 50+ countries since 2014, Vivid Vision systems are used by major ophthalmic pharmaceutical companies and leading research institutions. Published studies demonstrate VVP achieves 6.8× better precision than standard automated perimetry, 2× better fixation stability, and 99% adherence to at-home testing protocols. The platform has been evaluated by premier institutions including the Retina Foundation of the Southwest and Duke University Medical Center. Vivid Vision Perimetry is clinically validated and industry-ready for phase I and II ophthalmology trials.

Cassini Technologies B.V. is an ophthalmic diagnostic and surgical planning solutions company headquartered in The Netherlands with US operations in Massachusetts and Florida. The company specializes in corneal diagnostics and intraoperative guidance systems for cataract and refractive surgery. Their core product line includes the Cassini Ambient, a corneal topography and biometry device that captures anterior and posterior corneal data using multicolor visible LEDs combined with infrared illumination, enabling highly repeatable measurements for toric intraocular lens (IOL) planning and astigmatism management. The Cassini Connect OR platform integrates preoperative diagnostics with intraoperative guidance, presenting surgical reference information in the operating room and supporting workflow continuity. The system features iris registration technology for automated cyclotorsion compensation and direct integration with femtosecond laser-assisted cataract surgery (FLACS) platforms including CATALYS and LENSAR, streamlining data transfer and reducing transcription errors. Cassini's solutions are designed to improve surgical accuracy and predictability, particularly for toric IOL placement and astigmatism correction. The company works with cataract surgeons, refractive specialists, and surgical centers across the US and internationally, emphasizing user-friendly operation, fast image acquisition, and open platform architecture enabling partnerships with major ophthalmic equipment manufacturers including Leica Microsystems. Clinical evidence demonstrates improved outcomes in toric lens volume, reduced prediction error in IOL power calculations, and enhanced astigmatic outcomes comparable to prevalent biometry combined with intraoperative aberrometry.

Coreline Soft Co., Ltd. is a South Korean medical AI software developer specializing in diagnostic imaging analysis and clinical decision support. The company develops the AVIEW platform, a suite of AI-powered software solutions for detecting and analyzing pulmonary and neurological conditions from CT and other medical imaging modalities. Core product lines include AVIEW LCS Plus (lung nodule, emphysema, and coronary artery calcification detection), AVIEW LCS (lung nodule detection and characterization), AVIEW COPD (chronic obstructive pulmonary disease analysis), AVIEW CAC (coronary artery calcification scoring), AVIEW Lung Texture (pulmonary pattern analysis), AVIEW NeuroCAD (intracranial hemorrhage detection and diagnosis support), AVIEW ILA (interstitial lung abnormality analysis), AVIEW Modeler (3D medical image modeling and 3D printing), AVIEW RT ACS (organ auto-segmentation), and data management solutions including pseudonymization servers. The company serves healthcare facilities globally, with established partnerships in Europe, North America, and Asia-Pacific for lung cancer screening programs and clinical research. Solutions integrate with existing hospital PACS and clinical workflows to automate image interpretation and provide radiologists with quantitative diagnostic support. The company publishes peer-reviewed clinical research demonstrating product utility and has exceeded 500 clinical publications. Regulatory approvals and certifications are indicated by deployment in hospitals across multiple jurisdictions, though specific FDA 510(k) or CE mark designations are not explicitly stated in available content.

Eyenuk is a global AI-driven digital health company specializing in autonomous eye screening technology for detection of diabetic retinopathy, age-related macular degeneration, and glaucoma. The company develops deep learning algorithms for retinal image analysis and has pioneered the EyeArt® AI Eye Screening System, the world's most extensively validated autonomous AI tool for diabetic retinopathy detection, tested on over half a million patient visits and 2 million images in real-world clinical settings. EyeArt requires no expert human grading, dilation, or specialist interpretation—enabling complete imaging, grading, and reporting within a single office visit in under 60 seconds. The system integrates a fundus camera with proprietary deep learning and image quality assessment algorithms that robustly detect disease presence and extent per internationally recognized clinical scales. EyeArt holds FDA 510(k) clearance for autonomous diabetic retinopathy detection across multiple camera platforms, EU CE marking (Class IIb MDR certification), and Health Canada licensure. Recent validation studies demonstrate 91.3% sensitivity and 91.1% specificity for referable DR, and 98.5% sensitivity for vision-threatening DR, across 100,000+ consecutive patient encounters. The platform empowers primary care physicians, endocrinologists, nurses, and technicians to perform point-of-care screening without subspecialty training, addressing the critical gap in annual diabetic retinopathy screening compliance. Eyenuk collaborates with major research institutions, health systems (including NHS deployment), and safety-net providers. Additional products under development include EyeMark™ (progression tracking), EyeArt™ AMD, EyeArt™ Glaucoma, and EyeRead™ UWF (ultra-widefield lesion analysis).

Carbon Medical Technologies, Inc. (formerly Advanced UroScience, Inc.) designs and manufactures implantable and minimally invasive medical devices using proprietary pyrolytic carbon coating technology. Founded in 1994, CMT is one of only five organizations worldwide with a dedicated pyrolytic carbon coating facility. The company specializes in devices for urological and oncological applications, with over 25 years of clinical use across 55+ countries and treatment of more than 1.4 million patients. CMT's primary product portfolio includes Durasphere® (an injectable bulking agent for stress urinary incontinence treatment), BiomarC® fiducial and tissue markers for radiation therapy and breast lesion localization, BiomarC® Restore for post-lumpectomy guidance, and the newly launched InjecSURE® cystoscopic injection system with female-specific anatomical design for urethral injections. The company operates under ISO 13485 and cGMP-compliant quality systems, maintains a validated ISO Class 7 cleanroom, and provides contract manufacturing services including design consultation, materials expertise, cleanroom assembly, and regulatory guidance. CMT supports multiple sterilization methods and manages the full product lifecycle from development through final delivery, positioning itself as a specialized provider for minimally invasive urology and oncology procedures.

hearX Group develops and distributes digital hearing health technology for clinical, screening, occupational, and retail applications. The company specializes in evidence-based, clinically-validated digital audiometry solutions that enable hearing assessment without requiring soundproof booths, reducing time and infrastructure costs. Products serve multiple market segments: clinical settings for patient care enhancement, workplace hearing conservation programs for regulatory compliance, population-level hearing screening for early detection and intervention, and retail environments offering in-store and online hearing testing. The company is FDA-registered, ISO 13485 certified, HIPAA compliant, SOC 2 Type II certified, and holds registrations with SAHPRA and compliance certifications including GDPR and POPIA. Manufacturing and service capabilities include software development for digital diagnostics, cloud-based data management, and support for multi-user clinical workflows. The company operates U.S. headquarters in DeKalb, Illinois, with additional operations in South Africa.

Access Bio, Inc. is a global in vitro diagnostics (IVD) manufacturer headquartered in Monroe Township, New Jersey. The company specializes in rapid diagnostic tests and molecular diagnostics for infectious disease detection, with a primary focus on malaria, HIV, HPV, and COVID-19. Access Bio's product portfolio includes rapid point-of-care tests, COVID-19 antigen and molecular (PCR) assays, serology tests, and automated laboratory analyzers. The company has received multiple FDA Emergency Use Authorizations (EUA) for COVID-19 detection kits, including a 10-minute antigen test and molecular tests with results in 83 minutes or less. Access Bio serves international public health agencies, healthcare systems, and research organizations globally. The company holds FDA regulatory approvals and maintains manufacturing and distribution capabilities through established supply chain partnerships. Recent regulatory milestones include FDA-granted shelf-life extensions for the CareStart COVID-19 Antigen Home Test (extended to 21 months at 1–30°C storage). Access Bio is positioned as a leader in infectious disease diagnostics with operations across the US, South Korea, and other international markets. The company actively pursues partnerships with healthcare providers, educational institutions, and global health organizations to expand access to diagnostic solutions.

QuidelOrtho Corporation is a global in vitro diagnostics company providing diagnostic solutions across clinical laboratory, transfusion medicine, molecular testing, and point-of-care applications. The company offers over 550 assays across multiple testing modalities including real-time PCR, rapid lateral-flow immunoassays, automated immunohematology systems, and benchtop analyzers. Key product platforms include LYRA™ real-time PCR assays (open platform molecular testing), QUICKVUE™ rapid lateral-flow tests for infectious diseases and point-of-care diagnostics, TRIAGE™ System for point-of-care immunoassays, VITROS™ benchtop clinical chemistry systems, SOFIA™ 2 Analyzer for rapid diagnostics, ORTHO VISION™ Swift automated blood bank analyzers, ORTHO™ Workstation semi-automated immunohematology analyzer, and ORTHO OPTIX™ Reader for transfusion lab testing. The company serves clinical laboratories, hospitals, point-of-care settings, and home-testing markets in 140+ countries. QuidelOrtho recently completed acquisition of Lex Diagnostics, expanding its diagnostic portfolio. The company manufactures diagnostic instruments, reagents, and assays for infectious disease detection (virology, molecular, immunoassay), blood banking, clinical chemistry, and specialty testing. Products are regulated as in vitro diagnostic devices under FDA and international standards.